FIELD: medicine.
SUBSTANCE: invention relates to the use of tryptanthrin-6-oxime as a drug with cardioprotective activity.
EFFECT: expanding the arsenal of drugs with cardioprotective activity.
1 cl, 1 tab, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT RELIEVING POSTINFARCTION MYOCARDIAL REMODELING | 2020 |
|
RU2740895C1 |
| AGENT FOR RELIEVING POSTINFARCTION MYOCARDIAL REMODELING | 2022 |
|
RU2830221C2 |
| AGENT HAVING CARDIOPROTECTIVE ACTION AND 1,3-DISUBSTITUTED 2-AMINOBENZIMIDAZOLIUM HALIDES | 2013 |
|
RU2526902C1 |
| AGENT IMPROVING CARDIAC RESISTANCE TO ISCHEMIC AND FOLLOWING REPERFUSION INJURIES | 2012 |
|
RU2488404C1 |
| METHOD OF TREATING ISCHEMIC HEART DISEASE WITH DISTAL OR DIFFUSE AFFECTION OF CORONARY ARTERIES | 2011 |
|
RU2481839C2 |
| AGENT WITH NEUROPROTECTIVE ACTIVITY | 2019 |
|
RU2800955C2 |
| AGENT SIMULATING CARDIAC POSTCONDITIONING PHENOMENON | 2012 |
|
RU2502508C1 |
| MYOCARDIAL INFARCTION THERAPY | 2006 |
|
RU2355325C2 |
| AGENT POSSESSING ENDOTHELIUM PROTECTIVE ACTIVITY | 2014 |
|
RU2563622C1 |
| AGENT POSSESSING CARDIOPROTECTIVE ACTIVITY | 2019 |
|
RU2699039C1 |
Authors
Dates
2023-03-13—Published
2019-04-30—Filed